Brexit & Transition Period Statement
CareFlow Medicines Management Ltd (CMM) have investigated the consequences of Brexit known to date, and looked specifically at the issues that may arise following the end of the transition period which concludes 31st December 2020.
CMM is headquartered in Basildon, UK. All Customer Services and Support can be delivered within the UK on a continued and uninterrupted basis regardless of the outcome.
As the vast majority of our business is based in the UK, any potential Border/Tarif or trade issues would have minimal impact to the overall business and no impact on its capability and capacity to deliver business as usual.
We have also checked and ensured that none of our employees will be impacted by Brexit. We have checked with our Auditors regarding any potential further commercial impact and do not see any areas of concern.
In conclusion, although there is still some uncertainty as to the outcome and final position of Britain’s exit from the EU regarding a Deal or No Deal, as far as can be anticipated, we do not foresee any interruption of our services or support in the UK or other EU and non-EU countries regardless of the outcome of the final stage negotiations.
If your organisation requires a Supplier Preparedness Statement, please contact Jenny.McCarron@wellsky.com